CSI Market
Sign In | Register

Soleno Therapeutics Inc (SLNO) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access SLNO quarterly Cash Flow →
From Soleno Therapeutics Inc through Dec 31 2021, changes in Dec 31 2025's operating cash flow provide insight into underlying business performance trends.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income20.89
Depreciation & amortization2.02
Amortization of Other Assets0.04
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-14.03
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation45.85
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Change In Fair Value Of Preferred Stock Warrants-
Change In Fair Value Of Common Stock Warrants-
Induced Conversion Of Convertible Debt Expense-
Noncash Lease Expense0.61
Increase Decrease In Accrued Clinical Trial Site Costs-
Asset Acquisition Contingent Consideration Change In Fair Value5.54
Increase Decrease In Operating Lease Liability-0.31
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable-23.31
Increase (Decrease) in Accounts Payable3.61
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-4.74
Other Working Capital14.14
Other Noncash Income (Expense)0.02
Other net0.00
Payments for (Proceeds from) Other Operating Activities-3.52
Discontinued operations0.00
Net Cash flow from Operating Activities46.80
Investing Activities
Capital Expenditures-0.07
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities254.07
Payments to Acquire Marketable Securities-455.78
Real Estate Investments0.00
Proceeds From Security Deposit On Sublease-
Payments To Security Deposit On Sublease-
Proceeds From Sale Of Minority Interest Investment In Former Subsidiary-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-201.78
Financing Activities
Short-term debt Net0.00
Other borrowing transactions-0.06
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock333.07
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-283.77
Stock Issued-
Reduction In Initial Public Offering Costs Payable-
Capital Expenditures Incurred But Not Yet Paid-
Transaction Costs Includedin Accrued Liabilities-
Derecognition Of Warrant Derivative Liability-
Proceeds From Sale Of Common Stock And Common Stock Warrants-
Cash Paid For The Cost Issuance Of Common Stock And Common Stock Warrants-
Cash Paid For The Issuance Of Common Stock And Common Stock Warrants-
Cash And Cash Equivalents Period Increase Decrease Included In Current Assets Held For Sale-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents87.93
Accrued Liability For Cost Of Issuing Common Stock-
Proceeds From Sale Of Common Stock And Common Stock Warrants Net Of Costs-
Finance Lease Principal Payments-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities137.16
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow46.73
Total Cash Flow-17.82
4 historic quarters locked

Sign in to unlock the full Soleno Therapeutics Inc cash flow history.

Sign In Create Free Account

About Soleno Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20251231)
  • Filed with the SEC: February 25, 2026
  • Source: slno-20251231.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-071808

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License